NFA
TBPH icon

Nationwide Fund Advisors’s Theravance Biopharma TBPH Stock Holding History

Nationwide Fund Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-23,161
Closed -$793K – 1855
2017
Q3 		$793K Sell
23,161
-460
-2% -$15K ﹤0.01% 1930
2017
Q2 		$941K Sell
23,621
-27
-0.1% -$1.04K ﹤0.01% 1813
2017
Q1 		$871K Sell
23,648
-817
-3% -$26.1K ﹤0.01% 1845
2016
Q4 		$780K Buy
24,465
+770
+3% +$23.9K ﹤0.01% 1919
2016
Q3 		$859K Sell
23,695
-4,896
-17% -$136K ﹤0.01% 1881
2016
Q2 		$649K Buy
28,591
+10,059
+54% +$217K ﹤0.01% 2001
2016
Q1 		$348K Buy
18,532
+422
+2% +$6.91K ﹤0.01% 2275
2015
Q4 		$297K Buy
18,110
+1,741
+11% +$27.6K ﹤0.01% 2359
2015
Q3 		$180K Hold
16,369
– – ﹤0.01% 2615
2015
Q2 		$213K Sell
16,369
-860
-5% -$13.3K ﹤0.01% 2681
2015
Q1 		$299K Sell
17,229
-563
-3% -$10.3K ﹤0.01% 2496
2014
Q4 		$265K Sell
17,792
-288
-2% -$5.02K ﹤0.01% 2502
2014
Q3 		$417K Sell
18,080
-36
-0.2% -$1.04K ﹤0.01% 2315
2014
Q2 		$578K Buy
+18,116
New +$545K ﹤0.01% 2182

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Nationwide Fund Advisors's TBPH Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Theravance Biopharma (TBPH) in Q4 2017, closing a stake of 23,161 shares — an estimated $793K sold.

Nationwide Fund Advisors first reported a position in TBPH in Q2 2014 and held it in 14 quarters. The position peaked at $941K in Q2 2017. 84 funds tracked by Wall St. Rank hold TBPH as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Theravance Biopharma position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 23,161 Theravance Biopharma shares in Q4 2017, an estimated $793K.
  • Nationwide Fund Advisors first reported a position in Theravance Biopharma in Q2 2014 and held it in 14 quarters.
  • Nationwide Fund Advisors's Theravance Biopharma position peaked at $941K in Q2 2017.
  • 84 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.